PET FDG Assessment of Change in Atherosclerotic Plaques After Chemotherapy

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00742352

Enrollment

Registered

2008-08-27

Start date

2008-09-30

Completion date

Unknown

Last updated

2008-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Brief summary

The purpose of this study is to determine whether chemotherapy induces regression in atherosclerotic plaques in oncologic patients already undergoing PET FDG as part of their routine assessment.We will use PET FDG to assess whether the inflammation in atherosclerotic plaques is affected by chemotherapy and anti angiogenic therapy.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

65 Years to No maximum

Healthy volunteers

Inclusion criteria

* Women over the age of 65 diagnosed with metastatic breast cancer * Men over the age of 65 diagnosed with lung cancer

Exclusion criteria

* Patients under the age of 65 * Patients diagnosed with chronic inflammatory disease or chronic infection * Patients taking steroids and NSAIDS on a regular basis

Countries

Israel

Contacts

Primary ContactEinat Even Sapir, MD PhD

evensap@tasmc.health.gov.il972-3-6973532

Outcome results